MedTrace Logo

Factor IX as Adjunctive Therapy to Emicizumab (EMIX)

NCT05281718 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2025-01-20

No results posted yet for this study

Summary

This trial will enroll patients with severe hemophilia A. Experiments will be run in vitro by spiking patients' blood with different molecules (currently used and theoretically proposed as adjunctive therapy to emicizumab), therefore no more than minimal direct risk to patients is expected. This is a pilot preclinical study.

Conditions

Interventions

DRUG

Factor IX

Factor IX is on of the substrates of emicizumab.

Sponsors & Collaborators

  • Genentech, Inc.

    collaborator INDUSTRY

  • Tulane University

    lead OTHER

Principal Investigators

  • Maissa Janbain, MD, MS · Tulane University

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
12 Years
Max Age
120 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-08-01
Primary Completion
2024-03-07
Completion
2024-07-14
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05281718 on ClinicalTrials.gov